U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07167537) titled 'A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases' on Sept. 10.
Brief Summary: This study aims to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of OL-CD19-GDT in relapsed/refractory autoimmune diseases.
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Systemic Sclerosis (SSc)
Primary Sjogren's Syndrome
Intervention:
BIOLOGICAL: OL-CD19-GDT
OL-CD19-GDT will be given through IV bolus with ascending dose levels to determine the RDE and RP2D as specified in the protocol
Recruitment Status: RECRUITING
Sponsor: Beijing GoBroad Hospital
Information provid...